Navigation Links
VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent
Date:7/7/2009

BEDFORD, Mass., July 7 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat-K FAST(TM) imaging agent for measuring and monitoring Cathepsin K activity associated with disease progression and therapeutic response in vivo. Cathepsin K expression is well known as a key biomarker and therapeutic target in a range of bone-related diseases, including cancer metastasis to bone, as well as in atherosclerosis. The new Cat-K FAST(TM) agent is expected to significantly expand research and enhance drug development in these areas by enabling real time imaging of Cat-K activity.

Cat-K FAST(TM) represents an additional protease-sensing agent developed and commercially launched based on VisEn's new FAST ("Fluorescent Activatable Sensor Technology") in vivo agent platform. FAST agents are based on high-performance, activatable smaller molecules that combine biomarker specificity with optimized biocompatibility and pharmacokinetics for precise measurement and monitoring of key disease biomarkers in vivo.

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways. VisEn agent brands include ProSense(R), IntegriSense(TM), AngioSense(TM), OsteoSense(R) and MMPSense(TM). VisEn also offers its specialized in vivo agent labeling platforms, including its proprietary VivoTag(R) fluorescence labeling dyes for custom agent development, and its NanoSpark(R) labeling nanoparticles, all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging. All VisEn agents and labels, including the new Cat-K FAST(TM) agent, are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT(TM)) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems. VisEn agents are also designed to enable in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT(TM)) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo. VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including cancer research, inflammation, cardiovascular, skeletal and pulmonary disease. The Company also works with large pharmaceutical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.


'/>"/>
SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. VisEn Medical Raises $7 Million in Series B Financing
3. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
4. VisEn Launches Next-Generation Fast (Fluorescence Activatible Sensor Technology) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
5. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
6. Novozymes Launches Enzyme to Reduce Acrylamide in Food
7. Enova Medical Launches Exos Corporation
8. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
9. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
10. ThirdBiotech Networking Group Launches
11. BioReliance Launches Next-Generation Genotoxicity Screening Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017  Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
(Date:2/23/2017)... INDIANAPOLIS, Ind. (PRWEB) , ... February 23, 2017 ... ... Commercialization Award during the 12th annual Inventors Recognition Reception at Purdue Research ... annually to a faculty member in recognition of outstanding contributions to, and success ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... research tools, announced the acquisition of GenWay Biotech ... a comprehensive service and product offering for both ... acquisition will facilitate growth and enhance capabilities for ... antibodies, and ELISA assays will nicely complement ASB,s ...
(Date:2/22/2017)... ... February 22, 2017 , ... Kernel , a ... Systems, LLC (KRS) clinical development program. KRS is a neurotechnology spin-out from ... and clinical applications. The terms of the transaction were not disclosed. , ...
Breaking Biology Technology:
(Date:1/30/2017)... SAN FRANCISCO , Jan. 30, 2017   ... of the fastest growing genetic information companies, today announced ... 2016 financial results and provide 2017 guidance on Monday, ... a conference call that day at 4:45 p.m. Eastern ... call, Invitae,s management team will briefly review financial results, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 According to ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market is ... from 2016 to 2022. In 2015, Asia-Pacific dominated the ... public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):